

Athlone Crescent Pharmacy Limited
Abridged Unaudited Financial Statements
for the financial year ended 30 June 2025

Athlone Crescent Pharmacy Limited

CONTENTS

	Page
Director's Responsibilities Statement	3
Balance Sheet	4
Statement of Changes in Equity	5
Notes to the Financial Statements	6 - 9

Athlone Crescent Pharmacy Limited

DIRECTOR'S RESPONSIBILITIES STATEMENT

for the financial year ended 30 June 2025

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under that law, the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable him to ensure that the financial statements and Director's Report comply with the Companies Act 2014. He is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

Rory Donnellan
Director

31 July 2025

Athlone Crescent Pharmacy Limited

BALANCE SHEET

as at 30 June 2025

	Notes	2025 €	2024 €
Fixed Assets			
Intangible assets	5	80,208	97,708
Tangible assets	6	2,307	3,104
Fixed Assets		82,515	100,812
Current Assets			
Stocks	7	50,595	46,442
Debtors	8	196,825	150,191
Cash and cash equivalents		423,861	414,907
		671,281	611,540
Creditors: amounts falling due within one year	9	(53,702)	(90,826)
Net Current Assets		617,579	520,714
Total Assets less Current Liabilities		700,094	621,526
Capital and Reserves			
Called up share capital presented as equity		202	202
Share premium account	10	237,197	237,197
Retained earnings		462,695	384,127
Equity attributable to owners of the company		700,094	621,526

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

I as Director of Athlone Crescent Pharmacy Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 31 July 2025 and signed on its behalf by:

Rory Donnellan
Director

Athlone Crescent Pharmacy Limited
STATEMENT OF CHANGES IN EQUITY

as at 30 June 2025

	Called up share capital €	Share premium account €	Retained earnings €	Total €
At 1 July 2023	202	237,197	273,852	511,251
Profit for the financial year	-	-	110,275	110,275
At 30 June 2024	202	237,197	384,127	621,526
Profit for the financial year	-	-	78,568	78,568
At 30 June 2025	202	237,197	462,695	700,094

Athlone Crescent Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

1. General Information

Athlone Crescent Pharmacy Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 664832. The registered office of the company is The Crescent, Ballymahon Road, Athlone, Westmeath, N37WA06, Ireland which is also the principal place of business of the company. The principal activity of the company is that of a retail pharmacy. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 30 June 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Goodwill

Purchased goodwill arising on the acquisition of a business represents the excess of the acquisition cost over the fair value of the identifiable net assets including other intangible fixed assets when they were acquired. Purchased goodwill is capitalised in the Balance Sheet and amortised on a straight line basis over its economic useful life of 0 years, which is estimated to be the period during which benefits are expected to arise. On disposal of a business any goodwill not yet amortised is included in determining the profit or loss on sale of the business.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	12.5% Straight line
----------------------------------	---	---------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Athlone Crescent Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Operating profit	2025	2024
	€	€
Operating profit is stated after charging:		
Depreciation of tangible assets	797	797
Amortisation of goodwill	17,500	17,500
	<u>17,500</u>	<u>17,500</u>

4. Employees

The average monthly number of employees, including director, during the financial year was 4, (2024 - 6).

	2025	2024
	Number	Number
Director	1	1
Employees	3	5
	<u>4</u>	<u>6</u>

Athlone Crescent Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 June 2025

5. Intangible assets

	Goodwill €	Total €
Cost		
At 1 July 2024	175,000	175,000
At 30 June 2025	175,000	175,000
Provision for diminution in value		
At 1 July 2024	77,292	77,292
Charge for financial year	17,500	17,500
At 30 June 2025	94,792	94,792
Net book value		
At 30 June 2025	80,208	80,208
At 30 June 2024	97,708	97,708

6. Tangible assets

	Fixtures, fittings and equipment €	Total €
Cost		
At 1 July 2024	6,375	6,375
At 30 June 2025	6,375	6,375
Depreciation		
At 1 July 2024	3,271	3,271
Charge for the financial year	797	797
At 30 June 2025	4,068	4,068
Net book value		
At 30 June 2025	2,307	2,307
At 30 June 2024	3,104	3,104

7. Stocks

	2025 €	2024 €
Finished goods and goods for resale	50,595	46,442

The replacement cost of stock did not differ significantly from the figures shown.

8. Debtors

	2025 €	2024 €
Trade debtors	59,591	40,114
Amounts owed by group undertakings	106,163	80,310
Taxation	31,071	29,767
	196,825	150,191

Athlone Crescent Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 30 June 2025

9. Creditors	2025	2024
Amounts falling due within one year	€	€
Trade creditors	46,807	55,101
Taxation	3,991	2,273
Director's current account	2,904	-
Accruals	-	33,452
	53,702	90,826

10. Income Statement	Share premium account	Profit and loss account	Total
	€	€	€
At 1 July 2024	237,197	384,127	621,324
Profit for the financial year	-	78,568	78,568
At 30 June 2025	237,197	462,695	699,892

11. Capital commitments

The company had no material capital commitments at the financial year-ended 30 June 2025.

12. Director's remuneration	2025	2024
	€	€
Remuneration	100,551	70,634
Pension contributions	92,300	80,000
	192,851	150,634

13. Related party transactions

The following related party was identified during the period:

Geosoph Limited, a company with common directors and shareholders.
Included in debtors at year end is balance owing from Geosoph Limited €106,163 (2023 €80,310)

14. Parent company

The company regards Geosoph Limited as its parent company.

15. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

16. Approval of financial statements

The financial statements were approved and authorised for issue by the board on 31 July 2025.